Ernexa Therapeutics (ERNAW) Non-Current Deferred Tax Liability (2012 - 2017)

Ernexa Therapeutics (ERNAW) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $52000.0 in Q4 2017.

• Quarterly Non-Current Deferred Tax Liability rose 6.12% year-over-year to $52000.0 in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $52000.0 (up 6.12% YoY) and the FY2017 annual result came in at $52000.0, up 6.12% from the prior year.
• Non-Current Deferred Tax Liability improved to $52000.0 in Q4 2017, from $49000.0 in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $52000.0 in Q4 2017 to a low of -$11000.0 in Q4 2013.
• A 3-year average of $30000.0 and a median of $49000.0 in 2016 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2013 — Non-Current Deferred Tax Liability jumped 85.9% — and 2017, when it grew 6.12%.
• Tracing ERNAW's Non-Current Deferred Tax Liability over 3 years: stood at -$11000.0 in 2013, then jumped by 545.45% to $49000.0 in 2016, then rose by 6.12% to $52000.0 in 2017.
• The last three Non-Current Deferred Tax Liability figures came in at $52000.0 (Q4 2017), $49000.0 (Q4 2016), and -$11000.0 (Q4 2013), per Business Quant data.